Objective: To compare the peripapillary retinal nerve fiber layer (pRNFL) thickness and macular volume in patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and healthy controls.
Introduction
Optical coherence tomography (OCT) is a non-invasive, practical and powerful tool that provides information about the structure of the retina and the head of optic nerves. The technique is mainly based on the differential optical reflectivity and generates a cross-sectional image of the retina, the only visible part of the central nervous system (CNS). OCT provides a quantitative assessment of individual layers of the retina. The retinal nerve fiber layer (RNFL) consists of unmyelinated axons that form the optic nerve after exiting from the lamina cribrosa, and is the main focus of OCT studies. The recent development of spectral domain OCT (SD-OCT) provides shorter acquisition times and enhanced resolution allowing the detection of subtle changes (1) .
The pathogenesis of multiple sclerosis (MS) consists of inflammation and early neuroaxonal transection. The rapidly developing technology of OCT aids the detection and monitoring of neuroaxonal degeneration in MS and other CNS diseases such as neuromyelitis optica (NMO) spectrum disorders (NMOSD). The diagnostic criteria of NMOSD have been updated several times since the early optic neuritis (ON) + transverse myelitis complex. The latest defined clinical spectrum involves a wider CNS involvement. The distinction from MS was made after the antibody against water channel protein, aquaporin-4 has been shown (2) . Up to 80% percent of patients with NMO are seropositive. NMOSD patients have more severe vision loss in acute ON and poorer visual outcome compared to MS patients and the course of the disease is more aggressive (3) . The thinning of peripapillary RNFL (pRNFL) was first described in MS patients in 1999 (4) and NMO patients in 2008 (5) .
In this study we aimed to evaluate whether there might be any difference between seronegative/seropositive groups of NMOSD according to OCT findings compared to MS patients and healthy controls. Although the subject itself is not new, knowledge on the pattern of neurodegeneration in the Turkish population may add useful information about general features of NMOSD and MS with and without ON.
Materials and Methods

Study Design and Patients
This comparative, observational study was performed at a single referral center. The study and the protocols were approved by the Ethics Committee of Hacettepe University Faculty of Medicine, Ankara, Turkey (KA-120111). Twenty-seven patients with MS and 13 patients with NMOSD (10 seropositive, 3 seronegative) were recruited from Neuro-Immunology and NeuroOphthalmology Clinics of Hacettepe University, between October 2013 to September 2014. Informed consent was obtained from all patients and healthy controls. None of the patients had infectious, vasculitic, ischemic, toxic or hereditary ON. Patients aged older than 18 years who were eligible with a diagnosis of either clinically definite relapsing-remitting MS (RRMS) or NMOSD were included. RRMS and NMOSD diagnoses were made according to revised McDonald criteria and revised diagnostic criteria for NMO, respectively (6, 7) . Patients with a history of ocular diseases (macular degeneration, uveitis, glaucoma, diabetic retinopathy) and a history of ON for the past 4 months were excluded. Nineteen age and sex-matched healthy controls with neither ophthalmic nor neurologic diseases were recruited from the headache outpatient clinic or medical staff.
Statistical Analysis
All patients and controls were examined by the same neurologist and ophthalmologist. Full neuro-ophthalmological assessments including visual acuity (using a Snellen chart), color vision (with Ishihara test), pupillary examination, slit lamp biomicroscopy, and fundoscopy were performed. In addition to standard neuro-ophthalmologic examinations, automatized visual field testing with central 30-2 Swedish Interactive Threshold Algorithm standard program of the Humphrey Field Analyzer (Carl Zeiss Meditec Inc, Dublin, CA, USA) was performed in both eyes of the patients. Retinal layer imaging was performed using a commercial SD-OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany) device with ~840 nm wavelength. For SD-OCT, only those images with a signal-to-noise score higher than 25 dB were analyzed. Scans with misalignment, decentration of the measurement circle, and poor illumination or those out of focus were excluded from the analysis. Average thicknesses were calculated for pRNFL. To assess the pRNFL, a circular scan with a diameter of approximately 3.4 mm was performed after manually positioning the center on the middle of the optic disc ( Figure  1 ). The pRNFL Spectralis protocol generates a map showing the average thickness and maps with 6 sector thicknesses (superonasal, nasal, inferonasal, inferotemporal, temporal, and superotemporal) (8) . Macular volumes were quantified using the software of the (Figure 2 ). Three retinal volumes were obtained, centered on the foveola with radii of 1.5, 3, and 6 mm. Comparisons of the thickness of retinal layers and macula were performed between ON and healthy control eyes, between ON subgroups of NMOSD, and MS, and between seronegative and seropositive patients of NMOSD.
Non-parametric statistical methods were performed due to the small sample sizes; the Kruskal-Wallis test was used to compare the groups and the Dunn test used for pairwise comparisons. A p value of less than 0.05 was considered to be statistically significant.
Results
The patients' characteristics are described in Table 1 . A total of 59 subjects were included in the study, 13 NMOSD (12 females), 27 MS (19 females) and 19 healthy controls (13 females). The mean age of the NMOSD group was 38.1±11.6 years, the MS group was 33.0±9.01 years, and the healthy controls was 34.0±9.41 years (p>0.05). The median disease duration of patients with NMOSD was 4 (range, 1-15) years, and for patients with MS it was 7 (range, 1-21) years. All patients with NMOSD were under immunosuppressive treatment (rituximab n=4, azathioprine n=9), and 24 of 27 patients with MS were under disease-modifying treatment (oral n=2, parenteral n=22); the remainder (3 patients) was on pulse steroid treatment. Ten of thirteen (77%) patients with NMOSD and 20 of 27 (74%) patients with MS had at least one ON episode. The median number of ON episodes for patients with NMOSD and MS were 3 (1-9) and 2 (1-5), respectively. The median time between the last ON episode and OCT for patients with NMOSD was 2.5 (range, 1-12) years and for patients with MS it was 7 (range, 1-13) years. Bilateral optic nerve involvement was 50% for the NMOSD-ON group, 40% for the MS group, and only 1 patient with NMOSD had simultaneous bilateral ON. Visual acuity of NMOSD-ON eyes (mean 0.6) was worse than non-ON eyes of patients with NMOSD (mean 0.8), MS-ON eyes (mean 0.8) and MS-non-ON eyes (mean 0.8) (p<0.01).
The mean deviation (MD) indices were used for visual field assessments. The average visual field MD indices were significantly lower in NMOSD-ON eyes (-14.8±9.1 dB) compared to NMOSDnon-ON eyes (-5.5±4.4 dB) (p=0.003), MS-ON eyes (-5.6±7.8 dB) (p<0.01) and MS-non-ON eyes (-4.4±3.7 dB) (p<0.01) ( After at least one clinical episode of ON, the mean pRNFL thickness for patients with NMOSD and MS were lower than healthy controls, and patients with NMOSD had significantly lower pRNFL thickness compared with those with MS. Among 43 ON eyes (NMOSD n=15, RRMS n=28), the NMOSD group had a lower mean pRNFL thickness of 60 (range, 34-105) µm compared with the 85 (range, 41-109) µm in MS eyes and 99 (range, 88-109) µm (p<0.01) in healthy controls, and this difference was statistically significant in every quadrant (Table 4 ). Among patients with MS, eyes with ON showed thinner pRNFL values in all quadrants compared with non-ON eyes, but this difference only reached statistical significance in average values (p=0.03) ( Table 4) .
A comparison of the quadrants showed that temporal quadrants were thinner in all patient groups compared with the healthy controls (p<0.01). Non-ON eyes of the NMOSD group showed a pRNFL thickness of 58.7 (range, 30-81) µm compared with non-ON eyes of patients with MS 59.7 (range, 18-79) µm (p=0.2 not significant) and in comparison with healthy controls 75.5 (range, 57-104) µm (p=0.001).
Three of 13 patients with NMOSD were seronegative for NMO-immunoglobulin G (23% Patients with ON showed reduced color vision, and color vision was affected more severely in the NMOSD-ON group compared with MS-ON (p=0.004). Non-ON eyes of patients with NMOSD and MS showed no difference in color vision (p=0.17).
Discussion
Our primary objective was to compare pRNFL thickness and macular volume between patients with NMOSD, RRMS, and healthy controls, and to evaluate if the severity of pRNFL deficit or macular volume loss could help to distinguish patients with NMOSD earlier in their course of the disease. This cross-sectional study demonstrated that after at least one episode of ON, the thickness of pRNFL was affected in both NMOSD and MS, with temporal quadrants being the most prone areas. We also showed that temporal pRNFL thickness was reduced in patients with NMOSD and RRMS compared with healthy controls, even in patients who had had no previous attack of ON. The study showed that NMOSD was associated with a thinner pRNFL compared with MS, and even temporal pRNFL was thinner in unaffected eyes of both patient groups compared with healthy controls, which was also reported in a study comparing the retinal thickness in the unaffected fellow eyes of MS and AQP4 positive ON patients (9) . Furthermore, visual acuity, color vision and visual field indices were more reduced in ON eyes of patients with NMOSD compared with ON eyes of MS. Therefore, our findings showed that visual acuity in the eyes in NMOSD is more deteriorated than in eyes with MS with ON. This finding may show that ON in NMOSD causes considerably more harm to visual pathways than MS. Our findings are consistent with previous studies in the literature. Ratchford et al. (10) revealed substantial pRNFL thinning in NMOSD ON eyes relative to both RRMS ON eyes and control eyes, and they also determined more severe visual impairment. The authors found that a first episode of ON in NMOSD was estimated to cause 24 µm more loss of pRNFL thickness compared with ON episodes in RRMS. However, they found no difference in OCT parameters between non-ON eyes of RRMS or NMO with healthy controls. In our study, we found that temporal pRNFL thickness was reduced both in non-ON NMOSD and RRMS eyes compared with healthy controls.
In a study by Kersten et al. (11), even though the average pRNFL was normal, they found significant thinning of temporal pRNFL in Huntington disease, which was significantly correlated with the disease duration. They interpreted these findings with the hypothesis that the progression of the disease caused atrophy of the small retinal ganglion cells in the macula, which consequently affected the papillo-macular bundle located on the temporal aspect of the optic nerve that is affected by the disease either directly or as a result of damage to their cell bodies in macula. We think that the reason for finding that the temporal pRNFL thicknesses were reduced in the non-ON group, contrary to Ratchford et al.'s (10) findings, was because they did not study the temporal pRNFL, but average pRNFL instead, which would have shown the earlier signs of damage. In the study of Bichuetti et al. (12) , the authors revealed significantly lower levels of average pRNFL in patients with NMOSD compared with RRMS, and found that the pRNFL value of 41 µm was 100% specific for ON associated with NMOSD when compared with RRMS.
In a multicenter study that was performed to outline the disease patterns in seropositive and seronegative NMOSD, seropositive patients were found to have more severe clinical attacks (3) . A more severe loss of visual acuity was observed in seropositive patients. However, bilateral ON was more common in seronegative patients, as was simultaneous ON. In the final outcome though, no differences regarding outcomes of ON were observed between seropositive and seronegative patients (3). Another study comparing seronegative and seropositive groups showed no difference in pRNFL and ganglion cell layer (GCL) thicknesses (13) . In our study, we found that seronegative patients had lower average pRNFL values compared with seropositive patients. However, we had only 3 patients in the seronegative group, which would have affected the accuracy of our comparison.
In the study of Park et al. (14) , where they used retinal segmentation with SD-OCT, they revealed thinning of GCL plus the GCL + inner plexiform layer at all macular locations in the study groups when compared with healthy controls. These values were lowest in patients with NMOSD. They also found no statistically significant differences when the average pRNFL values were compared between NMOSD, MS, and isolated ON groups, but found significant differences in temporal and inferior pRNFL values.
Recent studies that were mainly focused on Alzheimer's disease and Parkinson's disease showed that, in neurodegenerative diseases, retinal single layer analysis was superior when outlining the retinal pathologies when compared with pRNFL thickness or central foveal thickness alone. These studies indicate that retinal pathology could exist as a thinning of neural tissues that can be shown with SD-OCT using retinal segmentation before they reach the optic nerve (15) . This is one of the limitations of our study; we did not use retinal segmentation and evaluate retinal single layer thicknesses because whole retinal thickness or pRNFL analysis alone may not show the earlier results in neurodegeneration. Another limitation is that we did not consider the disease durations and small sample sizes, especially for the seronegative NMOSD group.
In our study, ON was shown to cause a significant decrease in MD of VF (from -5.5±4.4 dB to -14.8±9.1 dB) in patients with NMOSD; however, patients with MS ON did not cause a statistically significant decline in those parameters. This supports the view that an attack of ON seems to cause more deterioration of the visual pathways in NMOSD compared with MS. Park et al. (14) also revealed a decline in MD levels in all groups of NMOSD, MS, and isolated ON groups, with the worst results being in the NMOSD group.
Our study revealed that both foveal (area in a 1.5 mm ETDRS ring) and total macular volume (area in a 6 mm ETDRS ring) were lower in both patients with MS and NMOSD compared with healthy controls. Besides, although not statistically significant, patients with NMOSD had thinner macular volumes compared with patients with RRMS (1.18±0.3 vs 1.82±2.07 µm 3 , respectively). Ratchford et al. (10) also reported reduced macular volumes in both the NMOSD and RRMS groups compared with healthy controls in their study.
Conclusion
In conclusion, our results show that both patients with NMOSD and MS with ON have decreased visual acuities, MD indices in VF testing, and pRNFL thickness, the deterioration being more significant in the NMOSD group. These findings suggest that visual pathways are more sensitive to the damage with episodes of ON in patients with NMOSD. The retina and the optic nerve may be at direct risk due to the existing antibodies. Our results also reveal that even if patients do not undergo ON, damage still exists, especially in pRNFL thickness in both patients with MS and NMOSD, similarly. This is an important issue suggesting that when patients are thought to be clinically silent, there remains an ongoing loss of retinal nerve fibers, suggesting a loss of dopaminergic neurons.
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